| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H21N5O3S |
| Molecular Weight | 387.456 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1N(CCCN2CCN(CC2)C3=NC=CC=N3)S(=O)(=O)C4=CC=CC=C14
InChI
InChIKey=MPLTZRTXQLNGED-UHFFFAOYSA-N
InChI=1S/C18H21N5O3S/c24-17-15-5-1-2-6-16(15)27(25,26)23(17)10-4-9-21-11-13-22(14-12-21)18-19-7-3-8-20-18/h1-3,5-8H,4,9-14H2
| Molecular Formula | C18H21N5O3S |
| Molecular Weight | 387.456 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Revospirone (BAY VQ 7813) is a pyrimidinylpiperazine derivative that acts as partial agonist at 5-HT1A receptors. Head shakes were reported after administration of revospirone in pigs, and once daily administration for 3-5 days led to a reduction in this head shake response. No behavioral alterations were observed. This compound was never marketed
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
